Advertisement
Australia markets close in 45 minutes

  • ALL ORDS

    7,803.80
    -95.10 (-1.20%)
     

  • ASX 200

    7,553.20
    -88.90 (-1.16%)
     

  • AUD/USD

    0.6400
    -0.0026 (-0.40%)
     

  • OIL

    84.47
    +1.74 (+2.10%)
     

  • GOLD

    2,397.60
    -0.40 (-0.02%)
     

  • Bitcoin AUD

    97,123.29
    +721.72 (+0.75%)
     

  • CMC Crypto 200

    1,284.80
    +399.26 (+43.77%)
     

  • AUD/EUR

    0.6016
    -0.0015 (-0.24%)
     

  • AUD/NZD

    1.0880
    +0.0005 (+0.05%)
     

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NASDAQ

    17,394.31
    -99.31 (-0.57%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • Dow Jones

    37,775.38
    +22.07 (+0.06%)
     

  • DAX

    17,837.40
    +67.38 (+0.38%)
     

  • Hang Seng

    16,209.57
    -176.30 (-1.08%)
     

  • NIKKEI 225

    37,120.25
    -959.45 (-2.52%)
     

This Top Growth Stock Is Targeting a Multi-Billion-Dollar Market. Here's What It Means for Investors

Prosper Junior Bakiny, The Motley Fool
·4-min read
This Top Growth Stock Is Targeting a Multi-Billion-Dollar Market. Here's What It Means for Investors

Vertex Pharmaceuticals (NASDAQ: VRTX) has made a fortune developing medicines for cystic fibrosis (CF), a rare disease that causes damage to the lungs. The company is awaiting approval for exa-cel -- a therapy for the blood disorder sickle cell disease -- which it developed in combination with CRISPR Therapeutics. Recently, these two longtime partners announced a new deal to target another disease, type 1 diabetes (T1D).

Continue reading